GSK plc (NYSE:GSK) Receives Consensus Rating of “Moderate Buy” from Analysts

GSK plc (NYSE:GSK) has been given an average recommendation of “Moderate Buy” by the ten ratings firms that are covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold rating and three have assigned a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $43.25.

Several research analysts have recently weighed in on the stock. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and lowered their price target for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Argus upgraded shares of GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Barclays upgraded shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research note on Friday.

Insiders Place Their Bets

In other news, major shareholder Plc Gsk bought 2,791,930 shares of the company’s stock in a transaction on Friday, September 27th. The stock was bought at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the transaction, the insider now directly owns 16,775,691 shares in the company, valued at $134,205,528. The trade was a 19.97 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in GSK. 1832 Asset Management L.P. lifted its holdings in GSK by 9.1% during the 1st quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company’s stock worth $132,000 after buying an additional 257 shares in the last quarter. Boltwood Capital Management increased its position in shares of GSK by 2.5% during the second quarter. Boltwood Capital Management now owns 11,133 shares of the pharmaceutical company’s stock worth $429,000 after acquiring an additional 270 shares during the period. First Affirmative Financial Network raised its stake in shares of GSK by 4.7% in the second quarter. First Affirmative Financial Network now owns 6,359 shares of the pharmaceutical company’s stock valued at $245,000 after acquiring an additional 283 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in GSK by 9.4% in the second quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company’s stock valued at $137,000 after purchasing an additional 303 shares during the period. Finally, Mesirow Financial Investment Management Inc. grew its stake in GSK by 2.0% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock worth $682,000 after purchasing an additional 323 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Down 3.0 %

Shares of NYSE:GSK opened at $33.35 on Monday. GSK has a 52-week low of $32.83 and a 52-week high of $45.92. The stock has a market cap of $69.12 billion, a P/E ratio of 21.66, a PEG ratio of 1.29 and a beta of 0.66. The business has a fifty day moving average of $39.08 and a two-hundred day moving average of $40.68. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be issued a $0.3928 dividend. This represents a $1.57 annualized dividend and a yield of 4.71%. The ex-dividend date is Friday, November 15th. This is an increase from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is 100.00%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.